Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 23- Open
- $60.53
- 52-wk high
- $62.13
- High
- $61.60
- 52-wk low
- $33.43
- Low
- $60.37
- Prev close
- $60.58
Smart money
Earnings
Earnings came in 3.9% above what analysts expected.
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $609.3M | $622.0M | $630.6M | $674.1M |
| Cost of what it sold | $1.3M | $1.2M | $1.2M | $268.2M |
| Gross profit | $609.3M | $622.0M | $629.4M | $405.9M |
| What it spent | ||||
| Research and development | $50.5M | $51.0M | $40.0M | $97.9M |
| Sales and admin | $118.7M | $164.3M | $159.0M | $161.9M |
| Other operating costs | $12.9M | $18.3M | -$202.1M | $13.1M |
| Total operating expenses | $182.1M | $233.6M | -$3.1M | $272.8M |
| What was left | ||||
| Operating profit | $427.2M | $388.4M | $632.5M | $133.0M |
| Interest on debt | $79.6M | $94.2M | $93.7M | $93.6M |
| Profit before tax | $444.2M | $355.9M | $468.3M | $81.5M |
| Tax | $156.0M | $142.0M | $173.0M | — |
| Net profit | $288.2M | $214.2M | $295.0M | $17.9M |
| EBITDA | $525.1M | $451.3M | $563.1M | $176.4M |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
News
What the news says
Coverage leans bearish
Tone of tracked coverage
Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock
Leans bearishAug 20Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity
NeutralAug 19Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale
NeutralAug 18